Immuron (IMRN) Share-based Compensation (IS) (2017 - 2023)
Immuron (IMRN) recorded quarterly Share-based Compensation (IS) of $2.0 million in Q3 2023, up 1249.86% quarter-over-quarter from $151687.1 in Q2 2023.
Immuron (IMRN) Share-based Compensation (IS) (2017 - 2023) Analysis & Trends
Immuron's Share-based Compensation (IS) history runs 6 years deep, the most recent figure standing at $2.0 million for Q3 2023.
- In Q3 2023, Share-based Compensation (IS) changed N/A year-over-year to $2.0 million; the TTM figure through Sep 2023 stood at $2.0 million (changed N/A YoY), while the FY2023 annual figure was $2.0 million, changed N/A from the prior year.
- Share-based Compensation (IS) was $2.0 million for Q3 2023 at Immuron, up from $151687.1 in the prior quarter.
- In the past five years, Share-based Compensation (IS) ranged from a high of $2.0 million in Q3 2023 to a low of -$42.9 billion in Q4 2021.
- Historically, Share-based Compensation (IS) has averaged -$5.4 billion across 5 years, with a median of $109827.2 in 2023.
- The sharpest annual moves came in 2021 and 2023: Share-based Compensation (IS) tumbled 202666646.42% in 2021, then surged 123.18% in 2023.
- A 5-year view of Share-based Compensation (IS) shows it stood at $6070.0 in 2019, then slumped by 448.6% to -$21160.1 in 2020, then plunged by 202666646.42% to -$42.9 billion in 2021, then surged by 100.0% to $2.0 million in 2022, then advanced by 2.07% to $2.0 million in 2023.
- The last three Share-based Compensation (IS) figures came in at $2.0 million (Q3 2023), $151687.1 (Q2 2023), and $2.0 million (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (IS) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.45 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 892,057.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 14.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Immuron | 921.61 Mn | 921.58 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 28, 2023 | 2.05 Mn |
| Sep 28, 2023 | 2.05 Mn |
| Jun 30, 2023 | 151,687.08 |
| Jun 30, 2023 | 151,687.08 |
| Dec 31, 2022 | 2.01 Mn |
| Dec 31, 2022 | 2.01 Mn |
| Jun 30, 2022 | 67,967.42 |
| Jun 30, 2022 | 67,967.42 |
| Dec 31, 2021 | -42.88 Bn |
| Dec 31, 2021 | -42.88 Bn |
| Jun 30, 2021 | 1.63 Mn |
| Jun 30, 2021 | 1.63 Mn |
| Dec 31, 2020 | -21,160.13 |
| Dec 31, 2020 | -21,160.13 |
| Dec 31, 2019 | 6,070.00 |
| Dec 31, 2019 | 6,070.00 |
| Dec 31, 2017 | -46,380.23 |
| Dec 31, 2017 | -46,380.23 |